Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer

Franco Figoli, Andrea Veronesi, Andrea Ardizzoni, Luciano Canobbio, Gioia Bruschi, Francesco Mazza, Vittorina Zagonel, Giovanni Lo Re, Riccardo Rosso, Silvio Monfardini

Research output: Contribution to journalArticlepeer-review


Twenty-seven evaluable patients with small cell lung cancer (SCLC) resistant to, or relapsed after induction combination chemotherapy (CT) were treated with etoposide (VPJ6) plus cisplatin (DDP). Previous treatment was: alternating CT with cyclophosphamide (C), adriamycin (A), methotrexate (M), procarbazine (P) (CAMP)/VP16, BCNU (B), hexamethylmelamine (H) (VP16BH) in 16 patients; C, A, vincristine (CAV) in 6 patients; C, A, and VP16 (CAVP16) in 5 patients. We observed 2 (7% complete responses (CR) and 9 (33% partial responses (PR). Duration of CRs was 8 and 14 weeks, respectively. PRs lasted a median of 22 weeks (range 16-44). Seven of 21 (33% patients previously treated with VP16 responded to DDP plus VP16 (D-V). These results confirm D-V regimen as active in SCLC patients even when heavily pretreated. Our 33 % response in patients who had VP16 in their induction treatment regimen provides further evidence of an important potentiating effect of DDP, as reported in animal system.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalCancer Investigation
Issue number1
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer'. Together they form a unique fingerprint.

Cite this